Study of oral medicine and probiotics for kidney disease in diabetes
Part of Hormones & metabolism, Kidney & urinary clinical trials.
This trial tests if an oral medication that absorbs toxins plus probiotics can reduce inflammation and slow kidney damage in people with diabetes-related kidney disease (DKD). It may help those with mild to severe kidney function loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 20 years or older
- You must have diabetes-related kidney disease with stable kidney function for at least 30 days
- Your estimated kidney function (eGFR) must be below 90
- You cannot have severe malnutrition, anemia, or active bleeding
- You cannot have had antibiotics or probiotics in the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an oral product (a “uremic toxin” absorber) plus probiotics to help slow the progression of chronic kidney disease. It may help by lowering harmful gut-related substances that can build up when kidney function is reduced.
This trial tests whether taking a probiotic supplement can slow down the decline of kidney function in people with moderate chronic kidney disease (CKD stages 3 and 4). If you have stable kidney disease and are not already taking probiotics, joining this study could help researchers find a new way to protect your kidneys.
This study looks at a gene marker (“lncRNA,” a natural molecule in the body) to see how well an oral absorbent, with or without probiotics, is helping people with chronic kidney disease (CKD) who also have blocked leg arteries. It may help doctors better measure treatment impact and tailor care.
This study tests whether an oral absorbent plus probiotics can improve gut health and circulation in people who have chronic kidney disease and symptomatic peripheral artery disease (PAD). It will also track changes in blood markers and how well blood vessels function.
This trial tests whether a special blend of probiotics and prebiotics (called a synbiotic) can improve gut health and reduce harmful waste products in the blood for people on hemodialysis.
This trial tests a new oral medication, coated aldehyde oxystarch, for people on dialysis. It aims to lower certain waste products in the blood that are hard to remove with standard dialysis, which may help reduce long-term complications.
Hear when a new Oral Uremic Toxin Absorbent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.